Tag: BIO TECH

Shares in Madrigal Pharmaceuticals (Nasdaq: MDGL) soared this week after the FDA granted accelerated approval of the company’s drug candidate Rezdiffra™ in the treatment of… [Read More]

Intense investor interest saw 13 million Cybin Inc (Nasdaq: CYBN) shares change hands in intraday trading on Thursday, up from its average of around four… [Read More]

Commercial stage biopharmaceutical company, TG Therapeutics (Nasdaq: TGTX), has presented data from its ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b… [Read More]

The therapeutic use of nature-derived psilocybin in mental health and wellbeing continues to rise in popularity. Psyence Group (CSE: PSYG) has announced this week that… [Read More]

 Kyverna Therapeutics (Nasdaq: KYTX) will collaborate with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label,… [Read More]

The FDA supports an accelerated approval pathway for Mesoblast Limited’s (Nasdaq: MESO) rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic… [Read More]

Biopharmaceutical company, FSD Pharma Inc. (Nasdaq: HUGE) has announced positive results from its Phase 1 study of Lucid-21-302 as a potential treatment to prevent disease… [Read More]

Mind Medicine Inc. (Nasdaq: MNMD) has been granted FDA Breakthrough Therapy Designation for its generalized anxiety disorder (GAD) treatment candidate, MM120 (lysergide d-tartrate). MindMed also… [Read More]

Parkinson’s disease remains one of the most prevalent neurodegenerative diseases worldwide, affecting more than one million people in the US alone. Inhibikase Therapeutics (Nasdaq: IKT)… [Read More]

Shares in Nexalin Technology (Nasdaq: NXL) rose almost 50% in intraday trading on Wednesday after the company announced positive topline results from its clinical study… [Read More]